United Therapeutics Corp (NASDAQ:UTHR)

CAPS Rating: 5 out of 5

A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

Results 1 - 20 of 24 : 1 2 Next »

Recs

0
Member Avatar asilverp (55.00) Submitted: 9/22/2014 12:55:20 AM : Outperform Start Price: $130.14 UTHR Score: -2.81

Headed by Martine Rothblatt, probably one of the more talented people on earth. Overvalued? maybe, but should do ok in the long term.

Recs

0
Member Avatar jsnms (25.29) Submitted: 12/25/2013 12:33:16 AM : Outperform Start Price: $112.56 UTHR Score: +3.32

Recent gap-up with high volume means it will do very well for the next six weeks.

Recs

0
Member Avatar genedom (97.90) Submitted: 9/9/2013 3:50:44 AM : Outperform Start Price: $73.47 UTHR Score: +53.80

Value

Recs

1
Member Avatar healthcarevalue (97.91) Submitted: 7/23/2013 8:02:57 PM : Outperform Start Price: $71.25 UTHR Score: +61.81

UTHR, United Therapeutics Corp, safe debt/equity ratio of 0.24, Return on Invested Capital (ROIC) twelve trailing months of 20.88 and from 2012 of even higher at 23.42, trailing price/earnings ratio at 12.7, reasonably priced and P/E is historically low looking back at valuations over the past nine years. Niche industry focus on chronic illness and life-threatening illness, including pulmonary arterial hypertension, infectious diseases, and lung diseases.

Recs

0
Member Avatar manirg (69.00) Submitted: 6/14/2013 1:12:06 PM : Outperform Start Price: $65.40 UTHR Score: +73.44

a good pick for long run

Recs

0
Member Avatar TerryHoodSr (56.41) Submitted: 5/29/2013 2:41:47 PM : Outperform Start Price: $63.78 UTHR Score: +77.37

3yr rev growth 25%
3yr EPS growth 100%

Recs

0
Member Avatar shaileshnita (69.65) Submitted: 4/22/2013 2:09:44 PM : Outperform Start Price: $61.11 UTHR Score: +81.50

It looks cheap.

Recs

0
Member Avatar picbois (98.92) Submitted: 6/24/2012 6:01:01 PM : Outperform Start Price: $47.71 UTHR Score: +117.67

The figures are amazing, many product protected by patent in disease that are not well served for medication.

Recs

1
Member Avatar Calinvestments (95.37) Submitted: 5/13/2011 1:29:33 PM : Outperform Start Price: $66.81 UTHR Score: +41.31

This is a small/mid cap high growth stock that should outperform the S&P during the bull market.

Recs

0
Member Avatar GTROwner (73.45) Submitted: 4/27/2011 11:32:51 PM : Outperform Start Price: $70.38 UTHR Score: +33.09

Will become the dominant player in the PAH market, strong pipeline in multiple high-profit potential orphan diseases like PAH, ILD, PF, Cancer, Stem Cell, and Virology. 30% annual growth over the last 5+ years.

Recs

0
Member Avatar HardnoseDotCom (69.47) Submitted: 4/25/2011 1:31:30 PM : Outperform Start Price: $69.52 UTHR Score: +33.30

low PEG, strong price uptrend

Recs

0
Member Avatar bez780 (< 20) Submitted: 7/29/2009 10:54:21 AM : Outperform Start Price: $42.96 UTHR Score: +91.31

new drugs

Recs

0
Member Avatar LexTNZorro (77.18) Submitted: 5/4/2009 3:21:31 AM : Outperform Start Price: $33.72 UTHR Score: +151.98

http://seekingalpha.com/article/133869-fda-clinical-trial-updates-watson-pharma-united-therapeutics-auxilium-dendreon?source=feed

Recs

0
Member Avatar fanomatic (< 20) Submitted: 4/20/2009 2:44:19 PM : Underperform Start Price: $28.44 UTHR Score: -210.60

This company is limited with products..... and competition for any existing product(s) will happen soon. Its medical device company (Medicomp) is really a small marginally profitable-if at all -firm run by a youngster who was given the job AND isn't a real board certified/practicing MD.
UTHR stock owners should better prepare to SELL now before and when the stock gets to the mid 40's.

Recs

0
Member Avatar wassercom (87.64) Submitted: 2/22/2009 9:15:12 AM : Outperform Start Price: $34.59 UTHR Score: +109.25

Pipeline looks good.

Recs

0
Member Avatar nysegal (66.51) Submitted: 8/5/2008 2:24:22 AM : Outperform Start Price: $55.78 UTHR Score: +65.17

UTHR is a terrific growth stock; accellerating earnings -- 80% in 08 and 68% in 09; recently reported fantastic earnings above street estimates.

Recs

0
Member Avatar ThxUT (< 20) Submitted: 3/13/2008 12:29:05 PM : Outperform Start Price: $39.76 UTHR Score: +164.08

UT leads the market in pulmonary hypertension with rapid growth and a better product than all the competitors.

Recs

0
Member Avatar SteelBreez99 (89.98) Submitted: 12/11/2007 5:47:28 PM : Outperform Start Price: $54.00 UTHR Score: +98.88

VALUE LINES - TIMELY STOCKS IN TIMELY INDUSTRIES

Recs

0
Member Avatar qasamm (34.47) Submitted: 12/11/2007 1:45:24 PM : Outperform Start Price: $53.69 UTHR Score: +101.68

Amazing leadership- many great suprises found in each annual report (no debt, diversity of pipeline, etc.)

Recs

0
Member Avatar MFClobberMeSilly (69.26) Submitted: 11/9/2007 8:27:36 AM : Outperform Start Price: $50.01 UTHR Score: +112.94

Best biomed

Results 1 - 20 of 24 : 1 2 Next »

Featured Broker Partners


Advertisement